Corvus Pharmaceuticals Reports $13.7 Million Net Loss in Q1 2026 Amid Increased R&D Expenses

Corvus Pharmaceuticals, Inc. reported a net loss of $13.7 million for the first quarter of 2026, a significant decline from a net income of $15.2 million in the same period of 2025. This shift is primarily attributed to a lack of revenue generation, as the company has not yet commercialized any of its product candidates. Total operating expenses increased to $14.9 million, up from $9.9 million year-over-year, driven by higher research and development costs, which rose to $11.2 million from $7.5 million. The increase in R&D expenses reflects ongoing clinical trials for its lead product candidate, soquelitinib, and other development programs.

The company’s financial position has improved markedly, with cash, cash equivalents, and marketable securities totaling approximately $236.7 million as of March 31, 2026, compared to $56.8 million at the end of 2025. This increase is largely due to a follow-on public offering completed in January 2026, which generated net proceeds of about $189.4 million. The total assets of Corvus Pharmaceuticals rose to $253.2 million, up from $71.1 million at the end of the previous fiscal year, reflecting a substantial increase in marketable securities.

Operationally, Corvus is advancing its clinical pipeline, particularly with soquelitinib, which is currently undergoing a Phase 3 trial for relapsed peripheral T cell lymphomas and a Phase 2 trial for atopic dermatitis. The company is also collaborating with Angel Pharmaceuticals to conduct a Phase 1b/2 trial for soquelitinib in China. The strategic focus on these clinical trials is expected to drive future growth, although the company acknowledges the need for additional capital to fund ongoing operations and development efforts.

As of March 31, 2026, Corvus had an accumulated deficit of $426 million, underscoring the financial challenges faced by early-stage biopharmaceutical companies. Management anticipates continued operating losses as they invest in the development of their product candidates. The company plans to raise additional capital through equity offerings and collaborations, although it recognizes the inherent risks and uncertainties in securing sufficient funding on favorable terms. Looking ahead, Corvus believes its current financial resources will support operations into the second quarter of 2028, but further financing will be necessary to sustain its development programs.